Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126012351 | 12601235 | 1 | I | 201501 | 20160715 | 20160728 | 20160728 | EXP | US-009507513-1607USA009541 | MERCK | 51.00 | YR | F | Y | 0.00000 | 20160728 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126012351 | 12601235 | 1 | PS | TEMOZOLOMIDE. | TEMOZOLOMIDE | 1 | 140 MG/M2, QD | Y | 22277 | 140 | MG/M**2 | SOLUTION FOR INJECTION | QD | ||||||
| 126012351 | 12601235 | 2 | C | THERAPEUTIC RADIOPHARMACEUTICAL (UNSPECIFIED) | UNSPECIFIED INGREDIENT | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126012351 | 12601235 | 1 | Glioblastoma |
| 126012351 | 12601235 | 2 | Glioblastoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126012351 | 12601235 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126012351 | 12601235 | Platelet count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126012351 | 12601235 | 1 | 201501 | 2015 | 0 | |
| 126012351 | 12601235 | 2 | 201501 | 0 |